Germline mutations that activate genes in the canonical RAS/MAPK signaling pathway are responsible for rare human developmental disorders known as RASopathies. Here, we analyzed the molecular determinants of Costello syndrome (CS) using a mouse model expressing HRAS p.G12S, patient skin fibroblasts, hiPSC-derived human cardiomyocytes, a HRAS p.G12V zebrafish model, and human fibroblasts expressing lentiviral constructs carrying HRAS p.G12S or HRAS p.G12A mutations. The findings revealed alteration of mitochondrial proteostasis and defective oxidative phosphorylation in the heart and skeletal muscle of CS mice that were also found in the cell models of the disease. The underpinning mechanisms involved the inhibition of the AMPK signaling pathway by mutant forms of HRAS, leading to alteration of mitochondrial proteostasis and bioenergetics. Pharmacological activation of mitochondrial bioenergetics and quality control restored organelle function in HRAS p.G12A and p.G12S cell models, reduced left ventricle hypertrophy in CS mice, and diminished the occurrence of developmental defects in the CS zebrafish model. Collectively, these findings highlight the importance of mitochondrial proteostasis and bioenergetics in the pathophysiology of RASopathies and suggest that patients with CS may benefit from treatment with mitochondrial modulators.
26 December 2024 in European Journal of Human Genetics
McArdle disease is a rare autosomal recessive disorder caused by mutations in the PYGM gene. This gene encodes for the skeletal muscle isoform of glycogen phosphorylase (myophosphorylase), the first enzyme in glycogenolysis. Patients with this disorder are unable to obtain energy from their glycogen stored in skeletal muscle, prompting an exercise intolerance. Currently, there is no treatment for this disease, and the lack of suitable in vitro human models has prevented the search for therapies against it. In this article, we have established the first human iPSC-based model for McArdle disease. For the generation of this model, induced pluripotent stem cells (iPSCs) from a patient with McArdle disease (harbouring the homozygous mutation c.148C>T; p.R50* in the PYGM gene) were differentiated into myogenic cells able to contract spontaneously in the presence of motor neurons and generate calcium transients, a proof of their maturity and functionality. Additionally, an isogenic skeletal muscle model of McArdle disease was created. As a proof-of-concept, we have tested in this model the rescue of PYGM expression by two different read-through compounds (PTC124 and RTC13). The developed model will be very useful as a platform for testing drugs or compounds with potential pharmacological activity.
Objective: To evaluate the effects of personalized multichannel tDCS on seizure frequency, severity, quality of life, and psychiatric comorbidities in patients with drug‐resistant focal epilepsy. Secondary goals include assessing the safety and feasibility of this approach. Methods: This open‐label pilot study involved 16 patients with drug‐resistant focal epilepsy. Patients underwent 3 cycles of personalized multichannel tDCS over 6 months, targeting the EZ defined by stereoelectroencephalography (SEEG). Each cycle consisted of five consecutive days of tDCS, with two daily sessions of 20 min each. The primary endpoint was a reduction in seizure frequency, with secondary endpoints addressing quality of life (QOLIE‐31 scores), seizure severity (NHS3 scores), and psychiatric comorbidities (NDDI‐E and GAD‐7 scales). Results: Across all participants, a statistically significant 20% reduction in seizure frequency was observed ( p = 0.044). Six patients (37%) were identified as responders (≥50% seizure reduction), with one achieving seizure freedom. The mean seizure reduction among responders was 68%. Significant improvements were noted in overall quality of life (QOLIE‐31, p = 0.009), with greater benefits for patients with poorer baseline scores. No overall significant changes were observed in depression, anxiety, and seizure severity scores, though individual variability was noted. The treatment was well tolerated, with mild adverse events, primarily skin‐related. Significance: Personalized multichannel tDCS shows promise as a noninvasive therapeutic option for drug‐resistant focal epilepsy, with benefits in seizure reduction and quality of life. Although results were variable, the method's safety and feasibility support further exploration through randomized controlled trials to refine protocols, better select potential responders' patients, and validate findings. Plain Language Summary: This study tested a personalized brain stimulation technique called tDCS in people with difficult‐to‐treat epilepsy. The treatment led to fewer seizures in some patients and improved their quality of life. The approach was safe and caused only mild side effects. These results suggest that this type of noninvasive brain stimulation may be a helpful new option for people who do not benefit from medication or surgery.
La dystrophie facio-scapulo-humérale (FSHD) est caractérisée par une faiblesse asymétrique et progressive de certains groupes de muscles, initialement ceux de la face, de la ceinture scapulaire et des bras. Les symptômes apparaissent généralement à la fin de la 2ème décade de la vie. Il existe une grande variabilité clinique et une pénétrance incomplète. Génétiquement, deux types de FSHD ont été décrits. Dans 95% des cas, la FSHD1 est associée à la contraction du macrosatellite D4Z4. Dans les 5% restants (FSHD2), il n’y a pas de diminution du nombre de répétitions D4Z4. Des mutations du gène SMCHD1 sont retrouvées pour 90% de ces patients. Dans les deux types de FSHD, une hypométhylation du locus est retrouvée.L’objectif de ma thèse fut de contribuer à l’amélioration du diagnostic de la FSHD et de mieux comprendre les mécanismes physiopathologiques sous-jacents. Ainsi, mon projet s’est articulé autour de deux axes. Le premier axe, translationnel, était basé sur l’exploration d’une cohorte importante de patients afin d’approfondir l’étude des mécanismes moléculaires dans la FSHD. Nous nous sommes notamment intéressés aux remaniements complexes et à la méthylation dans les différents types de FSHD. Le deuxième axe, plus fondamental, s’est intéressé aux aspects fonctionnels de la FSHD, en utilisant un protocole de différenciation des cellules souches à pluripotence induite de patients en fibres musculaires innervées afin d’en étudier le transcriptome et l’architecture chromatinienne associée aux variants SMCHD1. Ainsi, mes travaux ont permis une meilleure compréhension de cette pathologie complexe qu’est la FSHD, d’autant d’un point de vue moléculaire que fonctionnel.